Harvard Business School launches Precision Trials Challenge

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

HARVARD BUSINESS SCHOOL’s Health Care Initiative launched the Precision Trials Challenge, a competition to bring precision diagnostics and therapies to market more quickly.

“How can we develop business models that support the advancement of precision medicine? How can we get new therapies to market faster and at a lower cost? Our Precision Trials Challenge will help answer these questions by encouraging conversation and helping to put leading-edge ideas into practice,” said professor Richard Hamermesh.

The challenge is accepting applications through March 13. A panel of judges will select one winner and two runners-up to share a $100,000 prize. The winner will be announced in April and have the opportunity to present at the 2016 Personalized Medicine Conference.

The Precision Trials Challenge is funded by the Kraft Endowment for Advancing Precision Medicine, established last fall by a $20 million gift from the Kraft Family Foundation under the leadership of Foundation president Robert K. Kraft.

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login